High-dose Versus Low-dose Cyclophosphamide in Combination with G-CSF for Peripheral Blood Progenitor Cell Mobilization
1
조회
0
다운로드
1
인용
0
참고문헌
초록
Background : To compare the mobilizing effects and toxicities of two different doses of cyclophosphamide (CY) plus lenograstim (glycosylated G-CSF), we performed a prospective randomized study by enrolling patients suffering with either high-risk Non-Hodgkin's lymphoma (NHL) or breast cancer undergoing ablative chemotherapy. Methods : The NHL patients received 4 cycles of CHOP and the breast cancer patients received 2-3 cycles of FAC (FEC) adjuvant chemotherapy. Then, the patients were randomly allocated to receive CY 4 g/m2 (arm A) or 1.5 g/m2 (arm B) in combination with lenograstim. Large volume leukapheresis was carried out and it was continued daily until the target cell dose of 2×106 CD34+ cell/kg was reached. Results : Twenty-seven patients were enrolled in the study. The median number of leukaphereis sessions actually performed was 2.5 sessions in arm A and 3 sessions in arm B. The target cell dose was obtained with the median number of one leukapheresis session in both arms of the study (p=0.09). The collected number of CD34+ cells in the leukapheresis products was higher in arm A than arm B (22.4 vs. 9.9×106/kg, respectively, p=0.05). Grade III or IV leukopenia was present in 14/15 patients (94%) in arm A and in 1/12 patients (8%) in arm B (p<0.0001). Grade III or IV thrombocytopenia was present in 8/15 patients (54%) in arm A, but this was not present in any patients of arm B (p=0.0004). Neutropenic fever occurred in 6/15 patients (40%) in arm A, and in 1/12 patients (8%) in arm B (p=0.09). The hematological recovery of the leukocytes and platelets after transplantation was not statistically different between the two doses. Conclusion : Low-dose CY plus lenograstim is a safe and effective mobilizing regimen.
Abstract
Background : To compare the mobilizing effects and toxicities of two different doses of cyclophosphamide (CY) plus lenograstim (glycosylated G-CSF), we performed a prospective randomized study by enrolling patients suffering with either high-risk Non-Hodgkin's lymphoma (NHL) or breast cancer undergoing ablative chemotherapy. Methods : The NHL patients received 4 cycles of CHOP and the breast cancer patients received 2-3 cycles of FAC (FEC) adjuvant chemotherapy. Then, the patients were randomly allocated to receive CY 4 g/m2 (arm A) or 1.5 g/m2 (arm B) in combination with lenograstim. Large volume leukapheresis was carried out and it was continued daily until the target cell dose of 2×106 CD34+ cell/kg was reached. Results : Twenty-seven patients were enrolled in the study. The median number of leukaphereis sessions actually performed was 2.5 sessions in arm A and 3 sessions in arm B. The target cell dose was obtained with the median number of one leukapheresis session in both arms of the study (p=0.09). The collected number of CD34+ cells in the leukapheresis products was higher in arm A than arm B (22.4 vs. 9.9×106/kg, respectively, p=0.05). Grade III or IV leukopenia was present in 14/15 patients (94%) in arm A and in 1/12 patients (8%) in arm B (p<0.0001). Grade III or IV thrombocytopenia was present in 8/15 patients (54%) in arm A, but this was not present in any patients of arm B (p=0.0004). Neutropenic fever occurred in 6/15 patients (40%) in arm A, and in 1/12 patients (8%) in arm B (p=0.09). The hematological recovery of the leukocytes and platelets after transplantation was not statistically different between the two doses. Conclusion : Low-dose CY plus lenograstim is a safe and effective mobilizing regimen.
참고문헌 (22)
- "Peripheral blood progenitor cell transplantation", 6, pp.5~14 (2002)
- "Prospective randomized clinical trial comparing high-dose ifosfamide + GM-CSF vs high-dose cyclophosphamide + GM-CSF for blood progenitor cell mobilization", 25, pp.1141~1146 (2000)
- "Randomized trial of filgrastim versus chemotherapy and filgrastim mobilization of hematopoietic progenitor cells for rescue in autologous transplantation", 98, pp.2059~2064 (2001)
- "Mobilization of peripheral blood stem cells with high-dose cyclophosphamide or the DHAP regimen plus G-CSF in non-Hodgkin's lymphoma", 29, pp.285~290 (2002)
- "Phase III randomized study comparing 5 or 10 micro g per kg per day of filgrastim for mobilization of peripheral blood progenitor cells with chemotherapy followed by intensification and autologous transplantation in patients with nonmyeloid malignancies", 43, pp.50~57 (2003)
- "Filgrastim post-chemotherapy mobilizes more CD34+ cells with a different antigenic profile compared with use during steady-state hematopoiesis", pp.827~832 (1994), Bone Marrow Transplant 14
- "Randomized cross-over trial of progenitor-cell mobilization", 18, pp.1824~1830 (2000)
- "Peripheral blood progenitor cells for marrow reconstitution mobilization and collection strategies", 36, pp.611~624 (1996)
- "The biology and clinical uses of blood stem cells", 89, pp.2233~2258 (1997)
- "Development of a simplified single apheresis approach for peripheral blood progenitor cell transplantation in previously treated patients with lymphoma", pp.1693~1702 (1994), Linch DC
- "Progenitor-cell mobilization after low-dose cyclophsphamide and granulocyte colony-stimulating factor an analysis of progenitor cell quantity and quality and factors predicting for these parameters in 101 pretreated patients with malignant lymphoma", 15, pp.535~546 (1997)
- "Results of high-dose therapy and autologous bone marrow", stem cell transplantation during remission in poor-risk intermediate- and high-grade lymphoma, 1997, pp.90, 3844~3852
- "Survival benefit from high-dose therapy with autologous blood progenitor-cell transplantation in poor-prognosis non-Hodgkin's lymphoma", 14, pp.586~592 (1996)
- "High-dose chemotherapy and stem-cell rescue in the treatment of high-risk breast cancer prognostic indicators of progression-free and overall survival", 15, pp.2882~2893 (1997)
- "Efficacy, toxicity, and applicability of high-dose sequential chemotherapy as adjuvant treatment in operable breast cancer with 10 or more involved axillary nodes", 15, pp.2312~2321 (1997)
- "Results of a pilot study of 40 patients using high-dose therapy with hematopoietic rescue after standard-dose adjuvant therapy for high-risk breast cancer", 19, pp.331~336 (1997)
- "A comparison between 5 g", m2 and 7 g, pp.1992[DOI]
- "Analysis of human hematopoietic stem cell population", pp.364~370 (1994)
- "Recent advances in flow cytometry application to the diagnosis of hematological malignancy", 90, pp.2863~2892 (1997)
- "CD34 counts to predict the adequate collection of peripheral blood progenitor cells", 20, pp.587~591 (1997)
- "Subsets of CD34+ cells and rapid hematopoietic recovery after peripheral blood stem cell transplantation", 13, pp.1922~1932 (1995)
- "Therapeutic relevance of CD34 cell dose in blood cell transplantation for cancer therapy", 18, pp.1360~1377 (2000)